• Muhammad Abdullah Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Pakistan
  • Shoaib Alam Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore
  • Waleed Zafar Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore
  • Abdul Majid Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore


Background: Chemotherapy consisting of Adriamycin, Bleomycin, Vinblastine, and Doxorubicin (ABVD), which is the mainstay of treatment in Hodgkin’s Lymphoma (HL), is associated with both acute and long-term pulmonary toxicity primarily due to Bleomycin. Bleomycin induced pulmonary toxicity (BPT) is clinically detected using diffusing lung capacity for carbon monoxide (DLCO). The objective of this study was to evaluate changes in DLCO in HL patients before and after ABVD chemotherapy. Methods: Medical records of all adult HL patients treated with ABVD chemotherapy at a single centre in Lahore, Pakistan during the entire calendar year 2012 were analysed. Patients with pre-existing pulmonary dysfunction, history of thoracic surgery and smokers were excluded. Results:  A total of 179 HL patients were identified during the study period who received ABVD chemotherapy. Out of these, 93 (51.95%) patients had undergone both a pre- and post-chemotherapy DLCO measurements. The remaining patients had only one DLCO reading available and were not included in the analysis. The mean percentage difference between pre- and post-chemotherapy values for DLCO (5.49%; 95% confidence interval [CI] 1.56–9.43%) and for Haemoglobin-adjusted DLCO (8.24%; 95% CI 3.90–12.57%) were statistically significant at p<0.01. Diffusing lung capacity for carbon (DLCO) values declined from pre-treatment to post-treatment by 1–10% in 23 (24.7%) patients, by 10–20% in 19 (20.4%) patients, by 20–30% in 10 (10.8%) patients and >30% in 10 (10.8%) patients. After adjusting for age, a 1mg/m2 increase in dose of Bleomycin was significantly associated with 0.14%  (95% CI: 0.03–0.25%) decline in DLCO and 0.13% (95% CI: 0.10–0.26%) decline in haemoglobin-adjusted DLCO from pre-treatment value. Conclusions: Mild to moderate dysfunction in diffusion lung capacity is common after ABVD chemotherapy. DLCO and haemoglobin-adjusted DLCO value decreased with increasing age and increasing dose of Bleomycin.Keywords: Hodgkin’s Lymphoma, chemotherapy, diffusion lung capacity, Pakistan, cancer 

Author Biography

Muhammad Abdullah, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Pakistan

Internal medicine and Respiratory Therapist


Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36(1):252–9.

Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992;19(2 Suppl 5):38–44.

Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001;68(9):782–95.

Rosenow EC 3rd, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect 1995;10(2):86–95.

Snyder LS, Hertz MI. Cytotoxic drug-induced lung injury. Semin Respir Infect 1988;3(3):217–28.

Comis RL, Kuppinger MS, Ginsberg SJ, Crooke ST, Gilbert R, Auchincloss JH, et al. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 1979;39(12):5076–80.

Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989;16(3):679–85.

Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324(12):808–15.

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23(30):7614–20.

Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–84.

1Yagoda A, Mukherji B, Young C, Etcubanas E, Lamonte C, Smith JR, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972;77(6):861–70.

Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leung D, Portlock CS, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J ClinOncol 1996;14(4):1297–305.

Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12(2):297–305.

Brice P, Tredaniel J, Monsuez JJ, Marolleau JP, Ferme C, Hennequin C, et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 1991;2(Suppl 2):73–6.

Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM, et al. A prospective study of pulmonary function in Hodgkin’slymphoma patients. Ann Oncol 2008;19(10):1754–8.



Most read articles by the same author(s)